MedTrace Logo

Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

NCT06329063 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-04-11

No results posted yet for this study

Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Conditions

  • Healthy

Interventions

DRUG

Vasopressin

Administration of vasopressin (20 IU) (oral spray)

DRUG

Placebo

Administration of placebo (oral spray)

Sponsors & Collaborators

  • University of Electronic Science and Technology of China

    lead OTHER

Principal Investigators

  • Benjamin Becker, Dr · University of Electronic Science and Technology of China

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2025-06-01
Completion
2025-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06329063 on ClinicalTrials.gov